乳癌新辅助化疗后Ki-67变化与临床疗效的关系
RELATIONSHIP BETWEEN KI-67 EXPRESSION AND CLINICAL OUTCOME IN BREAST CANCER AFTER NEOADJUVANT CHEMOTHERAPY
李文金1
作者信息
- 1. 临沂市肿瘤医院乳腺二科,山东临沂276001
- 折叠
摘要
目的 探讨乳癌病人新辅助化疗后Ki-67的表达变化与临床疗效的关系.方法 选取Ⅱ～Ⅲ期的女性乳癌病人112例,术前均接受新辅助化疗.采用万科真空辅助旋切系统取样,应用免疫组化法检测新辅助化疗前后Ki-67的表达,分析其表达变化与临床疗效的关系.结果 乳癌病人新辅助化疗前Ki-67的高表达率为80.4％,低表达率为19.6％;新辅助化疗后Ki-67的高表达率为26.8％,低表达率为73.2％,新辅助化疗前后Ki-67的表达比较差异有统计学意义(x2=64.62,P＜0.05).新辅助化疗的临床有效率为45.5％,临床获益率为84.8％.Ki-67高表达的病人对新辅助化疗敏感性较高,化疗后Ki-67的表达由高转为低的病人临床疗效较好,化疗后Ki-67的表达没有变化或者由低转为高的病人临床疗效较差,Ki-67的表达变化与临床疗效有关(x 2=25.153,P＜0.05).结论 Ki-67表达很可能成为评估乳癌新辅助化疗效果的生物学指标,对化疗预后有提示作用.
Abstract
Objective To investigate the association of expression of Ki-67 with clinical effectiveness in breast cancer after neoadjuvant chemotherapy (NC).Methods One hundred and twelve female patients with stage Ⅱ-Ⅲ breast cancer were selected,and given a neoadjuvant chemotherapy before surgery.Samples were taken using EnCor vacuum assisted biopsy instrument,the expression of Ki-67-before and after NC-was detected employing immunohistochemistry,the association of Ki-67 with clinical efficacy was analyzed.Results Before NC,the high expression rate of Ki-67 was 80.4％,and the low of that was 19.6％;after NC,the high expression of Ki-67 was 26.8％,and the low of that was 73.2％,the differences in Ki-67 expression rates-before and after NC-were statistically significant (x2 =64.62,P＜0.05).The clinical effective rate for NC was 45.5％,and the clinical benefit rate was 84.8％.Patients with high expression of Ki-67 were sensitive to NC,and the clinical efficacy was better in those with decline of Ki-67 after NC,and the efficacy was poor for those with no changes of Ki 67 after NC or Ki-67 raised from low to high,the changes of Ki-67 expression were related to clinical effectiveness (x2=25.153,P＜0.05).Conclusion Ki-67 is likely to become a bioindicator in evaluation of neoadjuvant chemotherapy in breast cancer,which can predict the prognosis of the cancer after this kind of treatment.
关键词
乳房肿瘤/放化疗,辅助/Ki-67抗原/治疗结果Key words
breast neoplasms/chemoradiotherapy, adjuvant/Ki-67 antigen/treatment outcome引用本文复制引用
出版年
2017
NETL
NSTL
维普
万方数据